Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Iveric Bio’s AMD Drug Approved in US, Launch Set for This Month: Astellas
Astellas Pharma said on August 5 that it has received US regulatory approval for Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Avacincaptad pegol is a complement C5 inhibitor acquired…
To read the full story
Related Article
- FDA Approves Izervay’s Wider Label with No Dosing Duration Limit
February 14, 2025
- FDA Accepts Re-Submission of Izervay to Buttress Label
January 10, 2025
- FDA Turns Down Label Update for Izervay, Astellas Eyes Re-Filing
November 20, 2024
- Izervay Slows Geographic Atrophy Lesion Growth through 2 Years: Astellas
November 7, 2023
- Iveric Bio’s AMD Med Nets Positive PIII Topline Data in Geographic Atrophy: Astellas
September 20, 2023
- Iveric Bio’s AMD Drug Accepted for EMA Review: Astellas
August 21, 2023
- Astellas’ Iveric Bio Acquisition Completed
July 13, 2023
- Astellas Looks at Iveric Bio’s Eye Drug as 3rd Biz Pillar to Counter Xtandi Cliff
May 8, 2023
- Astellas to Snap Up Iveric Bio for US$5.9 Billion
May 1, 2023
BUSINESS
- Half of Drug Makers Reluctantly Support G1 Rule Overhaul: Jiho Survey
March 12, 2026
- FDA Resumes Review of Capricor/Nippon Shinyaku’s DMD Cell Therapy
March 12, 2026
- Hisamitsu Starts Promotion of Yaz AGs under Bayer Alliance
March 11, 2026
- Seagen ADC Patent Dispute Ends with Daiichi Sankyo Victory
March 11, 2026
- Seikagaku Re-Files Herniated Disk Drug with US FDA
March 11, 2026
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…